Spots Global Cancer Trial Database for e7080
Every month we try and update this database with for e7080 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC) | NCT02657369 | Thyroid Carcino... | Lenvatinib 24 m... | 18 Years - 99 Years | Eisai Inc. | |
| A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | NCT02702388 | Thyroid Cancer | Lenvatinib Lenvatinib matc... | 18 Years - | Eisai Inc. | |
| Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials | NCT03477175 | Solid Tumors | E7080 Comparator Drug Comparator Drug... | 18 Years - | Eisai Inc. | |
| A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | NCT04154189 | Osteosarcoma | Lenvatinib Ifosfamide Etoposide Lenvatinib | 2 Years - 25 Years | Eisai Inc. | |
| Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) | NCT02953743 | Unresectable He... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | NCT03006887 | Solid Tumors | lenvatinib pembrolizumab | 20 Years - | Eisai Inc. | |
| A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma | NCT04763408 | Carcinoma, Hepa... | Lenvatinib Sorafenib | 18 Years - | Eisai Inc. | |
| A Study to Assess the Safety and Efficacy of Lenvatinib as First-line Treatment in Participants With Unresectable HCC | NCT04297254 | Carcinoma, Hepa... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Post-Marketing Surveillance of Lenvima in Korean Patients | NCT02764554 | Differentiated ... | - | Eisai Inc. | ||
| Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) | NCT03433703 | Carcinoma, Hepa... | Lenvatinib | 18 Years - | Eisai Inc. | |
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma | NCT00121680 | Metastatic Mela... | E7080 | 18 Years - | Eisai Inc. | |
| A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | NCT03006926 | Hepatocellular ... | lenvatinib pembrolizumab (... | 18 Years - | Eisai Inc. | |
| A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | NCT03006926 | Hepatocellular ... | lenvatinib pembrolizumab (... | 18 Years - | Eisai Inc. | |
| A Trial of Lenvatinib Plus Pembrolizumab in Participants With Hepatocellular Carcinoma | NCT03006926 | Hepatocellular ... | lenvatinib pembrolizumab (... | 18 Years - | Eisai Inc. | |
| A Trial of Lenvatinib (E7080) in Radioiodine (131 I)-Refractory Differentiated Thyroid Cancer in China | NCT02966093 | Differentiated ... | Lenvatinib Placebo | 18 Years - | Eisai Inc. | |
| Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC) | NCT03433703 | Carcinoma, Hepa... | Lenvatinib | 18 Years - | Eisai Inc. | |
| Study to Assess the Long-term Safety of Lenvatinib Monotherapy, a Lenvatinib Combination Regimen, or a Comparator Treatment Arm to Cancer Participants in Eisai Sponsored Lenvatinib Trials | NCT03477175 | Solid Tumors | E7080 Comparator Drug Comparator Drug... | 18 Years - | Eisai Inc. | |
| A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | NCT04154189 | Osteosarcoma | Lenvatinib Ifosfamide Etoposide Lenvatinib | 2 Years - 25 Years | Eisai Inc. | |
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma | NCT00121680 | Metastatic Mela... | E7080 | 18 Years - | Eisai Inc. | |
| Phase 1b Trial of Lenvatinib Plus Pembrolizumab in Participants With Selected Solid Tumors | NCT03006887 | Solid Tumors | lenvatinib pembrolizumab | 20 Years - | Eisai Inc. | |
| Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma | NCT03173560 | Renal Cell Carc... | lenvatinib everolimus | 18 Years - | Eisai Inc. | |
| A Study of E7080 in Subjects With Solid Tumor | NCT01268293 | Cancer | E7080 | 20 Years - | Eisai Inc. | |
| A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010) | NCT05030506 | Renal Cell Carc... | Belzutifan Pembrolizumab Lenvatinib | 18 Years - | Merck Sharp & Dohme LLC | |
| A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma | NCT04154189 | Osteosarcoma | Lenvatinib Ifosfamide Etoposide Lenvatinib | 2 Years - 25 Years | Eisai Inc. | |
| An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors | NCT00280397 | Cancer: Solid T... | E7080 | 20 Years - 75 Years | Eisai Inc. | |
| A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma | NCT00121680 | Metastatic Mela... | E7080 | 18 Years - | Eisai Inc. | |
| An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors | NCT00280397 | Cancer: Solid T... | E7080 | 20 Years - 75 Years | Eisai Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
